Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development20221109220121
Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development
November 9, 20220 comments
Orlando, FL, Nov. 09, 2022 — Immune Therapeutics, Inc. (OTC PINK:IMUN) (“Immune” or “IMUN”) today announced that its Chief Executive Officer, Presid...
Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors20220927185925
Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors
September 27, 20220 comments
ORLANDO, FL, Sept. 27, 2022 — Immune Therapeutics, Inc. (OTC PINK:IMUN) (“Immune” or “IMUN”), a specialty pharmaceutical company involved in the acq...
Immune Announces Filing of 10-Q and Removal of Delinquency Flag on OTC Markets Stock Quotes20220825173318
Immune Announces Filing of 10-Q and Removal of Delinquency Flag on OTC Markets Stock Quotes
August 25, 20220 comments
ORLANDO, FL, Aug. 25, 2022 — Immune Therapeutics, Inc. (OTC PINK:IMUN) (“Immune” or “IMUN”), a pioneering pharmaceutical company involved in the acq...
Immune Therapeutics Appoints Chief Financial Officer and Chief Operating Officer20220804131900
Immune Therapeutics Appoints Chief Financial Officer and Chief Operating Officer
August 4, 20220 comments
ORLANDO, FL, Aug. 04, 2022 — Immune Therapeutics, Inc. (OTC PINK:IMUN) (“Immune” or “IMUN”), a specialty pharmaceutical company involved in the acqu...
Immune Therapeutics, Inc. Appoints Dr. Stephen Wilson as Chief Executive Officer20220722162600
Immune Therapeutics, Inc. Appoints Dr. Stephen Wilson as Chief Executive Officer
July 22, 20220 comments
ORLANDO, FL, July 22, 2022 — Immune Therapeutics, Inc. (OTC Pink: IMUN) (“Immune” or “IMUN”), a specialty pharmaceutical company involved in the acq...
Immune Therapeutics, Inc. Announces Expansion of its Board of Directors20220603172600
Immune Therapeutics, Inc. Announces Expansion of its Board of Directors
June 3, 20220 comments
ORLANDO, Fla, June 03, 2022 — Immune Therapeutics, Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the development, commercializa...